Centbutindole is a new antipsychotic drug which has a unique psychopharmacological profile different from the existing antipsychotic drugs available in the market. During clinical trials safety, tolerability and antipsychotic efficacy have been established in more than 350 schizophrenic patients treated at 7 centres (Deptt. of Psychiatry, K.G.s Medical College, Lucknow; NIMHANS, Bangalore; CIP, Ranchi; PGI, Chandigarh; Seth G.S. Medical College, Bombay; Medical College, Madurai; AIIMS, New Delhi.

Its antipsychotic efficacy profile compares well with haloperidol and trifluperazine. Besides, it did not produce severe extrapyramidal side effects as compared to haloperidol. In some recent clinical study comparing Centbutindole with haloperidol undertaken at KGMC, Lucknow Centbutindole also showed earlier onset of effect than haloperidol on positive and negative symptoms. There was no incidence of acute dystonia and akathisia reported with this drug in contrast to the occurrence of these embarrassing side effects seen with haloperidol. On comparison with risperidone, Centbutindole is equally effective in reducing positive and negative symptoms.

In conclusion, Centbutindole is a novel antipsychotic agent which offers an effective psychopharmacological tool to manage patients of schizophrenia. It is available for licensing.

(It is available for licensing)